HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Trump Says Anthropic No Longer Seen as National Security Threat 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SALT LAKE CITY, Jan. 21, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, chief financial officer, will provide an overview of Myriad’s financial performance for the fiscal second-quarter and provide a business update.
To listen to the call, interested parties in the United States may dial 800-676-1873 or +1 303-223-4378 for international callers. All callers will be asked to reference reservation number 21802448. The conference call also will be available through a live webcast and a slide presentation pertaining to the earnings call will also be available under the investor section of our website at www.myriad.com. A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21802448.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where high value diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer markets, diversifying its product portfolio through the introduction of new products and increasing its international contribution. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
